Role of Covered Stents and Drug Eluting Balloons In Dialysis Access
|
|
- Marylou Ward
- 6 years ago
- Views:
Transcription
1 Role of Covered Stents and Drug Eluting Balloons In Dialysis Access Joseph Habib, MD, FACS Assistant Professor Department of Surgery Division of Vascular and Endovascular Surgery University of Florida Jacksonville, FL Caution: Investigational Device. Not for sale in the US. Limited by Federal (or US) law to Investigational Use
2 None Disclosures
3 Hemodialysis Treatment for ESRD End-stage renal disease (ESRD) is treated in >600k patients in the US 1 >120k new ESRD patients annually 1 >$50B cost to Medicare 1 Hemodialysis represents a significant burden to healthcare system Over past 20 years, significant shift from AVG to AVF (Fistula First) 1-2 Both AVF and AVG failures necessitate access revisions Path from ESRD to AV Access Failures (US-2014) 1 ESRD End Stage Renal Disease RRT Renal Replacement Therapies HD Vascular Access Types 678k prevalent population 7% Peritoneal dialysis 30% Renal Transplant 63% Hemodialysis (HD) 19% Catheters 63% AVF - 18% AVG AVF and AVG Primary Patency mo: 48-80% 24-mo: 50-70% 1. Saran R, et al. US Renal Data System 2016 Annual Data Report: epidemiology of kidney disease in the United States. 11Am J Kidney Dis 2017;69:S1-S Tokars JI, et al. Semin Dial 2000;13: Al-Jaishi AA, et al. Am J Kidney Dis 2014;63: Palder SB, et al. Ann Surg 1985;202: Lumsden AB, et al. J Vasc Surg 1997;26: Munda R, et al. J Am Med Assoc 1983;249:
4 Stenosis in the Access Circuit National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) PTA first line treatment for stenosis Stent placement recommended: acute recoil after PTA stenosis recurring within 3 months patients at increased risk for surgery following vessel rupture KDOQI clinical practice guidelines (2006)
5 Stenosis in the Access Circuit 73% of cases of restenosis in the HD access circuit are secondary to in-stent restenosis No guidelines for treatment of in-stent restenosis Theoretically stent grafts provide a combination of endoluminal support to maintain vessel patency and biocompatible barrier to prevent cellular ingrowth Stent grafts provide a barrier to intimal hyperplasia, reduce in-stent restenosis Falk et al. 2016
6 Covered Stents in Dialysis Access Fluency Plus Vascular Stent Graft (Bard) FLAIR Endovascular Stent Graft (Bard) Viabahn Endoprosthesis (W.L. GORE)
7 Covered Stents Fluency Plus Vascular Stent Graft (BARD) Self expanding nitinol scaffolding with 2 layers of PTFE, carbon impregnated 5 mm to 13.5 mm diameters 20 mm to 120 mm lengths 8-10F compatible
8 Covered Stents FLAIR endovascular stent graft (BARD) Flared configuration, PTFE, carbon impregnated 6-9 mm diameters mm lengths 9F compatible
9 Covered Stents Gore Viabahn Endoprosthesis self expanding Nitinol skeleton covered with PTFE Propaten bioactive surface 5 mm-13 mm diameter mm lengths 6F-12F compatible
10 REVISE TRIAL RCT 293 patients (145 SG, 148 PTA) Viabahn Endoprothesis (GORE) vs. PTA to revise AV grafts TAPP (treatment area primary patency) 6 months: 51.6% SG vs 34.2 % PTA (p=0.006) Vesely et al. Journal of Vascular Surgery 2016
11 RENOVA Study Prospective, controlled trial 28 US sites, 270 patients enrolled, 191 completed (97 SG, 94 PTA) FLAIR Endovascular Stent Graft (BARD) vs PTA on revision of AV graft anastomotic stenosis through 2 years TAPP: 12 months: 47.6% SG vs. 24.8% PTA (p<0.001) 24 months: 26.9% SG vs 13.5% PTA (p<0.001) Haskal et al. J Vasc Interv Radiology 2016
12 RESCUE Study RCT 275 patients randomized (23 US sites) Fluency stent graft (BARD) compared with PTA for treatment of in-stent restenosis in AV grafts and fistulas TAPP: 6 months: 66.4% SG vs % PTA (p < 0.001) 12 months: 32.7% SG vs. 5.6% PTA 24 months: 15.6% SG vs. 2.2% PTA Falk et al. J Vasc Interv Radiology 2016
13 Stenosis in the dialysis circuit Uremia, oxidative stress, and inflammation When you arterialize a vein you create significant changes in flow dynamics which result in neo-intimal hyperplasia causing stenosis. Endovascular treatment of stenoses produce mechanical forces that induce more neointimal hyperplasia and fibrotic scar formation
14 Paclitaxel Cytotoxic drug Inhibits disassembly of microtubules during the M phase of the cell cycle, driving cells to apoptosis Theoretically this could lead to deceleration of neo-intimal hyperplasia and improve circuit patency Karnabatidis et al. 2017
15 Drug Eluting Balloons Paclitaxel-coated balloons Tested in the arterial bed with encouraging results in the SFA/popliteal location Nothing left behind principle no foreign material left behind to irritate the vascular wall. Karnabatidis et al. 2017
16 US DCB Device Overview Configurations Lutonix 035 (Bard) 4-7mm diameter mm length 1 IN.PACT Admiral (MDT) 4-7mm diameter mm length 2 Platform Lutonix PTA Admiral PTA Drug and Dosage Paclitaxel 2.0µg/mm 2 Paclitaxel 3.5µg/mm 2 Excipient / Coating Sorbitol / Polysorbate Urea Commercial Availability Worldwide Worldwide US Indication SFA & PA + ISR SFA & PA + ISR 1. IN.PACT Admiral introduced 150mm lengths July 2016.
17 Limited Available Literature for DEB in the Dialysis circuit Most reports employ the US-available DCBs (Bard Lutonix 035 and Medtronic IN.PACT DCB) One core lab-adjudicated multicenter randomized controlled trial (RCT) [Bard Lutonix AV Clinical Trial] Handful of single-center randomized and single-arm studies One planned core lab-adjudicated RCT [Medtronic IN.PACT AV Access Trial]
18 DEB in the Dialysis Circuit RCT 40 patients (20 DEB, 20 BA) Venous stenosis lesions both AVF/AVGs IN.PACT DEB TAPP (treatment area primary patency) 6 months (p<0.001) 70% DEB 25% BA Katsanos et al. J. Endvasc. Ther 2012
19 DEB in the Dialysis Circuit RCT 40 patients (DEB 20, BA 20) IN.PACT DEB vs PTA both AVF and AVGs TAPP at 12 months (p<0.001) 35% DEB vs. 5% BA Kitrou et al. European Journal of Radiology 2014
20 DEB in the dialysis circuit RCT comparing IN.PACT vs. standard PTA in failing AVFs 40 patients (20 DEB, 20 BA) TLR-free survival (308 d DEB vs. 161 d BA)(p=0.03) ACPP (access circuit primary patency) (DEB 270 d vs. BA 161 d) (p=0.04) Kitrou et al. J Vasc. Interv Radiology 2015
21 DEB in the dialysis circuit Single Center, retrospective analysis 39 patients, 61 interventions 20 AVFs, 19 AVGs Bard Lutonix PCB used TAPP at 6 months was 72.2% Kitrou et al. Cardiovas Interv. Rad. 2017
22 AV Access RCT: Lutonix AV Clinical Trial Design 1 Prospective, multicenter, randomized trial 23 global sites 285 subjects randomized 1:1 to PTA Primary Endpoints Efficacy: 6-month target lesion primary patency Safety: 30-day freedom from serious adverse events involving the access circuit Follow-up Fully-enrolled 1, 3, 6, 9, 12, 18, and 24 months 1. Presented by Treretola SO, LINC Leipzig, Germany 2017.
23 AV Access RCT: Lutonix AV Clinical Trial Key Inclusion and Exclusion Criteria 1 Inclusion Male and non-pregnant female Upper extremity AVF w/ clinical, physiological, or hemodynamic abnormality Fistula created 30 days 1 hemodialysis session 2 needles Catheter removed 30 days Lesion length 10cm 50% stenosis Successful predilation 4-12mm diameter vessel Exclusion Low extremity access Central veins Thrombosed access >2 lesions in circuit Secondary non-target lesion that cannot be successfully treated Central veins as a secondary lesion that is clinically significant Bare or covered stent in target or secondary non-target lesions 1. Presented by Treretola SO, LINC Leipzig, Germany 2017.
24 AV Access RCT: Lutonix AV Clinical Trial Key Patient and Lesions Characteristics 1 Patient Variable Lutonix 035 DCB (n=141) PTA (n=144) Mean Age 63.6y 61.0y Male 61.7% 59.0% Hypertension 94.3% 98.6% Diabetes Mellitus 58.2% 65.3% Dyslipidemia 60.3% 58.3% Current Smoking 13.5% 14.6% Peripheral Arterial Disease 9.9% 18.1% Coronary Artery Disease 30.5% 27.8% Lesion Variable Lutonix 035 DCB (n=141) 1. Presented by Treretola SO, LINC Leipzig, Germany 2017; p-values not presented. PTA (n=144) De Novo 30.5% 27.1% Tandem 2.8% 7.0% Target Lesion Length (mean ± SD) 28.4mm ± mm ± 18.69
25 AV Access RCT: Lutonix AV Clinical Trial Summary 1 First prospective, multicenter, randomized DCB AV access study First in fistula trial designed to incorporate a wide variety of lesions/fistula types 240-day Safety and Efficacy outcomes demonstrated: Safety outcomes non-inferior to PTA Target lesion primary patency 61.6% DCB vs. 49.4% PTA ( 12.2% p=0.02) 29.8% fewer interventions required to maintain target lesion patency in DCB arm Through 240 days, interventions required to maintain target lesion patency for DCB and PTA were 66 and 94, respectively 1. Presented by Treretola SO, LINC Leipzig, Germany Data shown are interim, site-reported and subject to change.
26 Overview Purpose Future IN.PACT AV Access IDE Trial To evaluate the safety and efficacy of the IN.PACT AV Access DCB compared to PTA for treatment of subjects presenting with de-novo or non-stented restenotic obstructive lesions of native AVF in the upper extremity. Design Prospective, global, multicenter, randomized, single-blinded study ~30 Global Sites (US, Japan & New Zealand) 330 patients 24 month follow-up 1:1 randomization Lesions up to 10 cm in length in the AVF Principal Investigators Robert Lookstein, MD (New York, USA) Andrew Holden (Auckland, New Zealand) Hiroaki Haruguchi, MD (Tokyo, Japan) 1.Katsanos K, et al. J Endovasc Ther 2012;19:
27 Endpoints Future IN.PACT AV Access IDE Trial Primary Safety Endpoint Serious Adverse Event Rate through 30 days: Defined as the Serious Adverse Event (SAE) rate involving the AV access circuit through 30 days post-procedure Primary Efficacy Endpoint Primary Patency Rate through 6 months: Defined as freedom from clinically-driven target lesion revascularization (CD-TLR) or access circuit thrombosis measured at 6 months postprocedure Estimated Start Second Half of Katsanos K, et al. J Endovasc Ther 2012;19:
28 Conclusions Hemodialysis represents a significant burden to healthcare system High rates of AVF and AVG failures necessitate frequent revascularization procedures When compared with standard PTA, stent grafts show superior TAPP for treatment of stenoses in AVGs/Fistulas DCB clinical data for AVF/G revision mostly limited to single-center studies One prospective, multicenter, RCT Lutonix AV Clinical Trial (Bard-sponsored) 1 Two single-center RCTs 2-4 One single-center prospective single-arm study 5 One single-center retrospective study 6 One single-center retrospective study on AVF ISR 7 DCB demonstrates improved outcomes over PTA in randomized studies While limited results show promise, larger RCTs needed 1. Presented by Treretola SO, LINC Leipzig, Germany Katsanos K, et al. J Endovasc Ther 2012;19: Kitrou PM, et al. Eur J Radiol 2015;84: Kitrou PM, et al. J Vasc Interv Radiol 2015;26: Patanè D, et al. J Vasc Access 2014;15: Kitrou PM, et al. Cardiovasc Interv Radiol 2017;40: Swinnen J, et al. J Vasc Access 2015;16:
IN.PACT AV Access IDE Study Full Baseline Data. Robert Lookstein, MD MHCDL New York, NY On Behalf of the IN.PACT AV ACCESS Investigators
IN.PACT AV Access IDE Study Full Baseline Data Robert Lookstein, MD MHCDL New York, NY On Behalf of the IN.PACT AV ACCESS Investigators Disclosures Speaker name: Robert Lookstein, MD... I have the following
More informationTechnical Aspects for Treating AV Dialysis Fistulae with the IN.PACT DCB. Andrew Holden Auckland Hospital Auckland, New Zealand
Technical Aspects for Treating AV Dialysis Fistulae with the IN.PACT DCB Andrew Holden Auckland Hospital Auckland, New Zealand LINC 2017 26 th January 2017 Disclosure Speaker name: Andrew Holden I have
More informationKonstantinos Katsanos, MSc, MD, PhD, EBIR
Konstantinos Katsanos, MSc, MD, PhD, EBIR Interventional Radiologist Patras University Hospital, Rion, Greece & Guy s and St. Thomas Hospitals, London, UK Honoraria from MEDTRONIC, BOSTON SCI Research
More informationCurrent Status of DCB Experience with Non- Femoropopliteal Applications (Dialysis, Tibial, Venous)
Current Status of DCB Experience with Non- Femoropopliteal Applications (Dialysis, Tibial, Venous) Saher Sabri, MD University of Virginia Health System Charlottesville, Virginia Dialysis vascular access
More informationLutonix AV Clinical Trial
Long Term Effects of LUTONIX 035 DCB Catheter Interim 24 Month Results Scott O. Trerotola, MD, for the Lutonix AV Investigators Stanley Baum Professor of Radiology Professor of Radiology in Surgery Associate
More informationLutonix AV Clinical Trial
Long Term Effects of LUTONIX 035 DCB Catheter Interim 24 Month Results Ta-Wei Su MD Vascular surgery CGMH Taiwan Disclosure I have the following potential conflicts of interest to report: Consulting Employment
More informationDisclosures. Consultant/Independent Contractor: B Braun, Teleflex, MedComp, Cook, Bard, WL Gore Royalty: Cook, Teleflex
Disclosures Consultant/Independent Contractor: B Braun, Teleflex, MedComp, Cook, Bard, WL Gore Royalty: Cook, Teleflex DCB in Hemodialysis Access Scott Trerotola, MD 2016: 50 th birthday of the AVF History
More informationQizhuang Jin. Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China
Safety and Efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (APERTO OTW ) for Arteriovenous Fistulae Stenosis: a Prospective, Multicenter, Randomized Controlled Trial APERTO
More informationLutonix in AV fistula and Early look AV IDE trial data
Lutonix in AV fistula and Early look AV IDE trial data Jackie P Ho Dept of Cardiac, Thoracic & Vascular Surgery National University of Singapore NUHS, Singapore Lutonix in AV fistula and final AV IDE trial
More informationCOVERA Vascular Covered Stents in the Management of Dysfunctional AV Access
COVERA Vascular Covered Stents in the Management of Dysfunctional AV Access Bart L. Dolmatch, M.D., FSIR Palo Alto Medical Foundation Mountain View, CA USA This presentation is being made on behalf of
More informationLUTONIX AV Clinical Trial
LUTONIX AV Clinical Trial A Prospective, Global, Multicenter, Randomized, Controlled Study Comparing LUTONIX 035 AV Drug Coated Balloon PTA Catheter vs. Standard Balloon PTA Catheter for the Treatment
More informationFirst experience with DCB for treatment of dialysis access stenosis The Greek experience
First experience with DCB for treatment of dialysis access stenosis The Greek experience D Karnabatidis Department of Interventional Radiology Patras University Hospital Patras, Greece Background Vessel
More informationProspective, randomized controlled study of paclitaxel-coated versus plain balloon angioplasty for the treatment of failing dialysis access
Prospective, randomized controlled study of paclitaxel-coated versus plain balloon angioplasty for the treatment of failing dialysis access Disclosure Speaker name:... I have the following potential conflicts
More informationJimmy Wei Hwa Tan, Surg, MD
Jimmy Wei Hwa Tan, Surg, MD Director, Department of Surgery Chief, Department of Cardiovascular Surgery Tainan An-Nan Municipal Hospital, China Medical University, Taiwan Disclosure I have the following
More informationWhich Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA
Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA Brian DeRubertis, MD, FACS Associate Professor of Surgery UCLA Division
More informationIs combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?
Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease? The REALITY trial G. Torsello Münster Disclosure Speaker name: G. Torsello... I have
More informationRecurrent lesions in AV access & Initial DCB experience in India
Recurrent lesions in AV access & Initial DCB experience in India Dr. Virender K Sheorain Consultant Interventional Radiologist Medanta-The Medicity Hospital Gurgaon, INDIA Disclosure Speaker name:... I
More informationDo we really need a stent in long SFA lesions? No: DEB is the answer
Do we really need a stent in long SFA lesions? No: DEB is the answer Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen Germany My Disclosures: Advisory Board: Medtronic-Invatec,
More informationInterventions for AV-Shunt stenosis: What works best PTA, Stent or DCB?
Interventions for AV-Shunt stenosis: What works best PTA, Stent or DCB? Martin Forlee Vascular Surgeon Cape Town Disclosure Speaker name: Martin Forlee I have the following potential conflicts of interest
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationUpdate from Korea on the Lutonix SFA registry 12 month data
Update from Korea on the Lutonix SFA registry 12 month data Prospective, Multicenter, Post-Market Registy Assessing the Clinical Use and Safety of the Lutonix Drug Coated Balloon in Femoropopliteal Arteries
More informationCOMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions. Dierk Scheinert
COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions Dierk Scheinert Department of Angiology University Hospital Leipzig, Germany Disclosure
More informationDisclosures. How many people have heard a talk on DCBs? By show of hands, how many people here have used a DCB?
Disclosures Drug Coated Balloons: How they work and what s the evidence? Christopher D. Owens, MD, MSc UCSF vascular surgery I am paid to talk about peripheral interventional procedures by Medtronic and
More informationLutonix AV Clinical Trial
Lutonix AV Clinical Trial Long Term Effects of LUTONIX 035 DCB Catheter 18 month Interim Results Scott O. Trerotola, MD Stanley Baum Professor of Radiology Professor of Surgery Associate Chair and Chief,
More informationDierk Scheinert, MD. Department of Angiology University Hospital Leipzig, Germany
The RANGER clinical trial programme: 12-month results from the RANGER RCT and first look at the COMARE I study of RANGER vs. IN.PACT for femoropopliteal lesions Dierk Scheinert, MD Department of Angiology
More informationReal-World Experience With Drug-Coated Balloons in AV Access
GLOBAL ROUNDTABLE Real-World Experience With Drug-Coated Balloons in AV Access Experts discuss the current use of DCBs in AV fistulas and review how upcoming trials may influence progress in this space.
More informationLong Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA
Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA Disclosures John R. Laird Within the past 12 months, I or my spouse/partner have had a
More informationIN ARTERIOVENOUS FISTULA FAILURE
DRUG ELUTING BALLOON ANGIOPLASTY IN ARTERIOVENOUS FISTULA FAILURE Nicola Troisi, MD GUIDELINES GUIDELINES VAS 2007 GUIDELINES VAS 2007 GUIDELINES VAS 2007 GUIDELINES VAS 2007 2007!!!!!!!!!! GUIDELINES
More informationDCB level 1 evidence review
DCB level 1 evidence review Raphaël COSCAS Vascular Surgery Department Ambroise Paré Hospital, AP-HP and Paris-Ouest University Boulogne-Billancourt, France Disclosure Speaker name: Raphael COSCAS I have
More informationPatient safety in the Eluvia DES and Ranger DCB programmes
Patient safety in the Eluvia DES and Ranger DCB programmes William A. Gray, MD Lankenau Heart Institute, Wynnewood, PA, USA Jan 22, 2019 Room 1 - Main Arena Disclosure Speaker name: William Gray I have
More informationMerits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁
Merits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁 Contents DES in SFA DES in BTK DEB in SFA DEB in BTK Current status of covered stent
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationDrug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
More informationThe Role of LUTONIX 035 DCB in AV Fistula Dysfunction Management in our Practice
The Role of LUTONIX 035 DCB in AV Fistula Dysfunction Management in our Practice Dr Kate Steiner Consultant Interventional Radiologist East and North Hertfordshire NHS Trust Disclosure Speaker name: Dr
More informationTHE SCIENCE BEHIND DRUG COATED BALLOONS OUTCOMES
THE SCIENCE BEHIND DRUG COATED BALLOONS OUTCOMES THE IDEA AND THE TECHNOLOGY FRANCESCO JATTA, PH.D. PROGRAM MANAGER DISCLOSURES I have the following potential conflicts of interest to report: Consulting
More informationDrug- Coated Balloons for the SFA: Overview of Technology and Results
Drug- Coated Balloons for the SFA: Overview of Technology and Results NCVH Latin American 2015 Bogota, Colombia April 9-11, 2015 Brian G. DeRubertis, M.D. Associate Professor of Surgery Division of Vascular
More information4/29/2012. Management of Central Vein Stenoses. Central Venous Stenoses and Occlusions
Central Venous Stenoses and Occlusions Management of Central Vein Stenoses Robert K. Kerlan Jr. M.D. Professor of Clinical Radiology and Surgery University of California San Francisco Key Questions What
More informationOne Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller
One Year after In.Pact Deep: Lessons learned from a failed trial Prof. Dr. Thomas Zeller Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: x Consulting:
More informationTOBA II 12-Month Results Tack Optimized Balloon Angioplasty
TOBA II 12-Month Results Tack Optimized Balloon Angioplasty William Gray, MD System Chief, Cardiovascular Division Main Line Health, Philadelphia, PA Dissection: The Primary Mechanism of Angioplasty Lesions
More informationPromise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD
Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD Associate Professor of Vascular Surgery University of New South Wales Sydney,
More informationCOVERA covered stent to treat stenosis in arteriovenous fistula: 6-month results from the prospective, multi-center, randomized AVeNEW study
COVERA covered stent to treat stenosis in arteriovenous fistula: 6-month results from the prospective, multi-center, randomized AVeNEW study Panagiotis Kitrou MD, MSc, PhD, EBIR Consultant Interventional
More informationMaking BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD
Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD Faculty Disclosure Thomas Zeller, MD For the 12 months preceding this presentation, I disclose the following types of
More informationDCB in the treatment of av-accessa single center prospective study
DCB in the treatment of av-accessa single center prospective study Dr. med. Tobias Steinke Schön Klinik Fachzentrum Gefäßchirurgie, Düsseldorf Disclosure Speaker name: Dr. med. Tobias Steinke I have the
More informationOutcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry Marianne Brodmann, MD Head of the Clinical Division of Angiology Department of Internal Medicine Medical University
More informationUpdate on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria
Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee Marianne Brodmann, MD Medical University Graz Graz, Austria Critical Limb Ischemia Infrapopliteal arterial disease is a leading source
More informationChristian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide
2-Year Results Of The Tack Optimized Balloon Angioplasty (TOBA) Trial For Fem- Pop Lesions Demonstrates Safety and Efficacy Of The Tack Endovascular System In Repairing Focal Post-PTA Dissections Christian
More informationRobert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015
Robert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015 Disclosure I have nothing to disclose Randomized Controlled Studies In SFA Technology: What s The Best Tool For
More information12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany
12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany Disclosure Speaker name: Gunnar Tepe I have the following potential conflicts
More informationAll arteriovenous access circuits, whether native vein
Summary of the Gore REVISE Clinical Study This nationwide study reports on the safety and effectiveness of the GORE VIHN Endoprosthesis for the treatment of stenoses and thrombotic occlusions involving
More informationProven Performance Through Innovative Design *
Proven Performance Through Innovative Design * Deliver Our Next Generation AV Covered Stent Results The COVERA Vascular Covered Stent builds upon proven technologies from the category leader in AV Access.
More informationDURABLE. CONSISTENT. SAFE. IN.PACT Admiral Drug-Coated Balloon
DURABLE. CONSISTENT. SAFE. Drug-Coated Balloon THE SCIENCE BEHIND THE OUTCOMES DCB has proven, long-term durable outcomes across multiple clinical trials, as well as across complex patient and lesion types.
More informationDrug-coated balloons in BTK:
Drug-coated balloons in BTK: Where do we stand and what are the open questions? Dr. Marc Bosiers LINC 2019 - Leipzig My disclosures x o I do not have any potential conflicts of interest to report o I have
More informationThe latest evidences from the DES trials in peripheral arterial disease
The latest evidences from the DES trials in peripheral arterial disease Michael D. Dake, MD Thelma and Henry Doelger Professor Stanford University School of Medicine Disclosure Speaker name: Michael D.
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
More informationDrug Elution, Data, and Decisions
Drug Elution, Data, and Decisions What the data tell us about how to integrate drug-eluting technology into our daily practice. BY GARY ANSEL, MD, AND JOHN A. PHILLIPS, MD The use of drug-eluting technology
More informationCurrent Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis
Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis Osamu Iida, MD From the Kansai Rosai Hospital Cardiovascular Center, Amagasaki City, Japan. ABSTRACT: Approximately
More informationDrug Eluting Balloon for AVF Angioplasty : Does it work?
Drug Eluting Balloon for AVF Angioplasty : Does it work? Dr Kiang Hiong TAY (MBBS, FRCR, FAMS, FSIR) Head & Senior Consultant, Dept of Diagnostic Radiology, Singapore General Hospital Director Interventional
More informationDCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes Carlos Mena, MD FACC FSCAI Associate Professor of Medicine - Cardiology Director Cardiac
More informationPHARMACOLOGICAL TREATMENT OF ARTERIAL RESTENOSIS
PHARMACOLOGICAL TREATMENT OF ARTERIAL RESTENOSIS PACLITAXEL VS RAPAMYCIN Paclitaxel essentially freezes the microtubules that are in place during cell division. The cells cannot complete cell division
More informationIs a Stent or Scaffold Necessary in The SFA?
1 2 3 Is a Stent or Scaffold Necessary in The SFA? Stents were developed to optimize acute results after angioplasty Specifically, stents are universally accepted to manage flow limiting dissections and
More informationMaximizing Outcomes in a complex population with Drug-coated balloon
Maximizing Outcomes in a complex population with Drug-coated balloon March 13, 2018 Chumpol Wongwanit, MD Siriraj Hospital, Mahidol University, Bangkok, Thailand LINC Asia-Pacific 2018, Hong Kong Disclosure
More informationBalloon Expandable Covered Stents. Suddenly a Crowded Space
Novel Balloon Expandable Covered Stents for Aorto-iliac Occlusive Disease: New Trial Data makes for an Interesting Balloon Expandable Covered Stents Comparison in Aorto-iliac Occlusive Disease: Andrew
More informationClinical benefits on DES Patient s perspectives
Clinical benefits on DES Patient s perspectives Dr. Skyi Pang Vascular Surgeon Department of Surgery Pamela Youde Nethersole Eastern Hospital Hong Kong Disclosure Speaker name: Skyi Pang... I have the
More informationDisclosures. Rational Selection of Endovascular Options for the SFA and Popliteal: What Works Where and for How Long?
Rational Selection of Endovascular Options for the SFA and Popliteal: What Works Where and for How Long? UCSF Vascular Symposium 2017 April 6-8, 2017 San Francisco, CA Disclosures Consulting, Speakers
More informationMICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES. Medtronic Further. Together
DRUG-COATED BALL0ON TREATMENT FOR PATIENTS WITH INTERMITTENT CLAUDICATION: INSIGHTS FROM THE IN.PACT GLOBAL FULL CLINICAL COHORT MICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES Medtronic Further. Together
More informationNew Data to Shape the Era of Drug Elution in Peripheral Interventions
New Data to Shape the Era of Drug Elution in Peripheral Interventions William A. Gray MD Director of Endovascular Services Columbia University Medical Center New York Lower Extremity Endovascular - Interventions
More informationISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany
ISR-treatment The Leipzig experience with purely mechanical debulking Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich I have the following
More informationVessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA
Vessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA Disclosure Statement of Financial Interest Within the past 12 months,
More informationThe importance of scientific evidence. Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern
The importance of scientific evidence Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner... I have the following potential
More informationLessons learnt from DES in the SFA is there any ideal concept so far?
Wednesday, January 25, 2017 - Time: 11:49-11:55 DEEP DIVE SESSION: Lower limb interventions (part II) Lessons learnt from DES in the SFA is there any ideal concept so far? S.Müller-Hülsbeck, MD, EBIR,
More informationTurbo-Power. Laser atherectomy catheter. The standard. for ISR
Turbo-Power Laser atherectomy catheter The standard for ISR Vaporize the ISR challenge In-stent restenosis (ISR) Chance of recurring 7 115,000 + /year (U.S.) 1-6 Repeated narrowing of the arteries after
More informationBIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort
BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort Prof. Dr. Gunnar TEPE, Klinikum Rosenheim, Germany CCI on behalf of the BIOLUX P-III Investigators Disclosure
More informationMEET M. Bosiers K. Deloose P. Peeters. SFA stenting in 2009 : The good and the ugly What factors influence patency?
MEET 2009 SFA stenting in 2009 : The good and the ugly What factors influence patency? M. Bosiers K. Deloose P. Peeters 1 TASC II 2007 vs TASC 2000 Type A Type B Type C Type D 2000 < 3 cm 3-5 cm < 3 cm
More information*PTA Failure: Recoil >30% stenosis or more than 2 PTA s within 3 mo. Bart Dolmatch, MD
The views presented reflect those of the author/presenter and do not necessarily reflect those of ASDIN nor serve as an endorsement of safety, efficacy or applicability of said procedure. the Endovascular
More informationEfficacy of DEB in Calcification and Subintimal Angioplasty
Efficacy of DEB in Calcification and Subintimal Angioplasty Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC Div of Cardiovascular Intervention and Research Cardiovascular Center, Korea University
More informationDCB in my practice: How the evidence influences my strategy. Yang-Jin Park
DCB in my practice: How the evidence influences my strategy Yang-Jin Park Associate Professor Division of Vascular Surgery, Department of Surgery Samsung Medical Center Sungkyunkwan University School of
More informationKonstantinos Katsanos, MSc, MD, PhD, EBIR. Consultant Interventional Radiologist Guy's and St.Thomas' Hospitals, NHS Foundation Trust
Konstantinos Katsanos, MSc, MD, PhD, EBIR Consultant Interventional Radiologist Guy's and St.Thomas' Hospitals, NHS Foundation Trust King's Health Partners, London, United Kingdom Nothing to declare Anatomy
More informationAlternative concepts for drug delivery in BTK arteries the LIMBO project
Alternative concepts for drug delivery in BTK arteries the LIMBO project Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany 1 Disclosure Speaker s name: Dierk
More informationBioMimics 3D in my Clinical Practice
BioMimics 3D in my Clinical Practice M Lichtenberg M.D. Vascular Centre Arnsberg / German Venous Centre Arnsberg CAUTION: Investigational Device. Limited by Federal (or United States) Law to Investigational
More informationLUTONIX DCB in AV Access: A Single Center Experience
LUTONIX DCB in AV Access: A Single Center Experience Dr Kate Steiner Consultant Interventional Radiologist East and North Hertfordshire NHS Trust Disclosure Speaker name:... I have the following potential
More informationUpdate on the Ranger clinical trial programme
Update on the Ranger clinical trial programme Dierk Scheinert, MD Universitätsklinikum Leipzig, Leipzig, Germany on behalf of the RANGER SFA investigators Disclosure Speaker s name: Dierk Scheinert I have
More informationUpdate on the role of drug eluting balloons
Update on the role of drug eluting balloons William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular Research
More informationVIRTUS: Trial Design and Primary Endpoint Results
VIRTUS: Trial Design and Primary Endpoint Results Mahmood K. Razavi, MD St. Joseph Cardiac and Vascular Center Orange, CA, USA IMPORTANT INFORMATION: These materials are intended to describe common clinical
More informationESVB State of the art: DES, DCB and the role of debulking. Gunnar Tepe, Rosenheim
ESVB 2013 State of the art: DES, DCB and the role of debulking Gunnar Tepe, Rosenheim DES I Sirocco Sirolimus coating, quick release Duda et al., J Vasc Surg 2002; 106: 1505-1509 20 DES II Strides Everolimus
More informationThe Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience
The Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany Disclosure Speaker name: Dierk Scheinert I have
More informationThe Evolution of SFA Treatment Strategy with IN.PACT DCB
The Evolution of SFA Treatment Strategy with IN.PACT DCB JOS VAN DEN BERG, MD OSPEDALE REGIONALE DI LUGANO LUGANO, SWITZERLAND RAPHAEL COSCAS, MD HÔPITAL AMBROISE PARÉ BOULOGNE BILLANCOURT, FRANCE ROBERTO
More informationDCB + BMS is not a DES
DCB + BMS is not a DES Fabrizio Fanelli, MD, EBIR Professor of Radiology Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy Disclosures Consultant
More informationThe role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium
The role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium Disclosures Speaker name: Frank Vermassen I have the following potential
More informationEvidence-Based Optimal Treatment for SFA Disease
Evidence-Based Optimal Treatment for SFA Disease Endo first Don t burn surgical bridge Don t stent if possible Javairiah Fatima, MD Assistant Professor of Surgery Division of Vascular and Endovascular
More informationAccurate Vessel Sizing Drives Clinical Results. IVUS In the Periphery
Accurate Vessel Sizing Drives Clinical Results IVUS In the Periphery Discussion Iida O, et. al. Study Efficacy of Intravascular Ultrasound in Femoropopliteal Stenting for Peripheral Artery Disease With
More informationMichael K. W. Lichtenberg MD, FESC on behalf of KANSHAS 1 investigators; Tepe G, Müller-Hülsbeck S, Deloose K, Verbist J, Goverde P, Zeller T
Interim 30-day analysis from the KANSHAS 1 study of the novel KANSHAS drug coated balloon for treatment of femoropopliteal occlusive disease; a latest first-in-human study Michael K. W. Lichtenberg MD,
More informationBTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration
BTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration M Sapoval, C Del Giudice, C Dean Interventional Radiology Dep Hôpital Européen Georges Pompidou APHP, Paris, France IMPORTANT
More informationManagement of In-stent Restenosis after Lower Extremity Endovascular Procedures
Management of In-stent Restenosis after Lower Extremity Endovascular Procedures Piotr Sobieszczyk, MD Associate Director, Cardiac Catheterization Laboratory Cardiovascular Division and Vascular Medicine
More informationThe drug-eluting balloon superficial femoral artery-long study THE DEB SFA-LONG STUDY
The drug-eluting balloon superficial femoral artery-long study THE DEB SFA-LONG STUDY Safety and efficacy of the Drug Eluting Balloon (DEB) for the treatment of the Superficial Femoral Artery (SFA) ischemic
More informationThe latest generation DEB
The latest generation DEB V. Riambau, MD. PhD Prof. and Chief of Vascular Surgery Division, Cardiovascular Institute, Hospital Clínic of Barcelona University of Barcelona Consultant: Bolton Medical/ Medtronic/
More informationClinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry
Clinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry Alexander Zimmermann Department of Vascular and Endovascular Surgery Klinikum rechts der Isar
More informationDrug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND
Drug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND Drug eluting stents and balloons Endovascular treatment now becoming more popular for treatment
More informationEndovascular Options in Critical Limb Ischemia: Below The Knee Therapies
Endovascular Options in Critical Limb Ischemia: Below The Knee Therapies Bret N. Wiechmann, MD FSIR FAHA FSVM Vascular & Interventional Physicians Gainesville, Florida Disclosures Consultant: Medcomp Bard
More information2 Year Results from the MDT SFA Japan Trial - DCB vs. standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA
2 Year Results from the MDT- 2113 SFA Japan Trial - DCB vs. standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA Osamu Iida, MD - Kansai Rosai Hospital, Hyogo, Japan Hiroyoshi Yokoi,
More information